ALX ONCOLOGY HOLDINGS INC

For the period ended Mar 31, 2026. Filed May 8, 2026.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Mar 31, 2026 · Filed May 8, 2026

ALXO$1.29+11.3%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Condensed Consolidated Balance Sheets

(in thousands, except share and per share amounts)

	March 31,	December 31,
	2026	2025
Assets
Current assets:
Cash and cash equivalents	$32,284	$16,373
Short-term investments	108,040	28,417
Prepaid expenses and other current assets	5,240	5,937
Total current assets	145,564	50,727
Property and equipment, net	1,050	1,200
Long-term investments	28,783	3,494
Other assets	2,931	3,625
Total assets	$178,328	$59,046
Liabilities and stockholders’ equity
Current liabilities:
Accounts payable	$3,854	$4,914
Term loan, current	5,217	5,217
Accrued expenses and other current liabilities	11,107	14,422
Total current liabilities	20,178	24,553
Term loan, non-current	3,295	4,532
Other non-current liabilities	3,508	3,980
Total liabilities	26,981	33,065
Commitments and contingencies (Note 12)
Stockholders’ equity
Common stock, $0.001 par value; 1,000,000,000 shares authorized as of March 31, 2026 and December 31, 2025; 134,540,741 and 54,388,022 shares issued and outstanding as of March 31, 2026 and December 31, 2025, respectively	135	54
Additional paid-in capital	892,201	748,716
Accumulated other comprehensive income (loss)	(245)	28
Accumulated deficit	(740,744)	(722,817)
Total stockholders’ equity	151,347	25,981
Total liabilities and stockholders’ equity	$178,328	$59,046

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.